COPENHAGEN, DENMARK, August 12, 2026 /EINPresswire.com/ — Again today announced the acquisition of Genomatica (Geno), uniting Again’s cutting-edge biomanufacturing scale-up capabilities with Geno’s world-class AI discovery and design platform.
Key highlights of the transaction include:
– One end-to-end AI and computation stack for biomanufacturing: the acquisition unlocks Geno’s world-class computational capabilities in the field of de novo molecule discovery and design. Combining two decades of in silico pathway and strain design, as well as predictive machine learning analytics experience, with Again’s AI-driven bioprocess design suite – creating the industry’s most complete artificial intelligence design engine.
– Closing the loop on scale-up: the hard challenge is not simulating, but scaling. By merging Geno’s full-stack simulation capabilities with Again’s scale-up modeling, cutting-edge engineering and execution expertise, the combined platform does what AI-only labs can’t – it designs and scales.
– Accelerated deployment across a range of novel feedstock sources: The integrated entity dramatically compresses the timeline from de novo pathway design to industrial execution, providing the rapidly growing biomanufacturing sector with high-throughput deployment across diverse, abundant feedstocks.
– Important geopolitical timing: The acquisition comes at a critical time for biomanufacturing, amidst reshoring momentum driven by the U.S. BIOSECURE Act and an accelerating $15 billion federal funding commitment to domestic bio-infrastructure.
Again, the technology company that designs and scales multi-feedstock pathways to make the products the world runs on, today announced it has acquired Genomatica (Geno), the pioneer in industrial bioprocess engineering. Terms of the transaction were not disclosed. The acquisition is one of the most significant consolidations in industrial biotechnology to date, bringing two of the field’s most advanced companies under one roof, and marking a major augmentation of Again’s capabilities.
For years, Again has been building toward a single vision: designing feedstock independent, efficient and reliable pathways to make the products the world depends on. The acquisition of Geno accelerates that vision bringing capabilities that will immediately turbocharge Again’s commercial & technical offerings for its array of global customers.
At the core of the deal is data. Again is acquiring Geno’s entire AI and computational biotech platform, including an unmatched patent portfolio and data spanning experimental results, structural and scale-up insights, and development outcomes. That data flows directly into Again’s computational engines, sharpening the accuracy of its models and compressing the time from idea to market for new products. More and better data makes the platform smarter, and the smarter platform will move even faster.
The combined company now operates across the full arc of production, from pathway discovery to industrial-scale manufacturing. Commercially, that gives Again a diversified model with three ways to create value: licensing technology where it scales, co-developing production pathways where they are mission-critical and selling products from existing & upcoming assets, thus building a business that captures value at every stage.
Max Kufner, CEO of Again, said: “AI is revolutionizing biology, but algorithms are only as good as their ability to translate into real-world, commercial-scale execution. Geno pioneered AI and computational biotechnology for molecule discovery and design. By integrating that with our scale-up platform and novel feedstock technologies, we are building the world’s leading biomanufacturing platform, unlocking novel products and supply-chains that industries critically need.”
ENDS
About Again
Again is a technology company redefining how everyday products are made. Again harnesses AI and computation to discover, simulate, and scale novel biomanufacturing technologies. With multiple real-world assets online, Again combines a unique skillset: combining AI and compute with engineering and upscaling. Not just designing but also delivering scientific breakthroughs. Again currently operates across Copenhagen, Munich and Houston, and develops technologies for partners across the industrial, personal and home care, food, and feed markets.
About Genomatica (Geno)
Genomatica (Geno) is a pioneer in industrial bioprocess engineering. Founded in 1998, Geno has commercialized biological processes to produce widely used chemicals and materials, building one of the deepest proprietary bioprocess datasets in the industry and an enviable patent portfolio. Its technology is used by manufacturers and leading consumer products companies worldwide. As part of this acquisition, Genomatica’s technology, IP, and commercial footprint will be fully integrated into the Again platform. All existing Genomatica partners will continue to be supported throughout the transition.
Aimee Soulsby
Burlington PR
email us here
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
